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oeen Abedin, MD
os Angeles, California
one biology has developed increasing importance in vas-
ular biology, and vice versa. The link begins in the embryo,
hen bone develops on a vascular reticulum produced by
ngiogenic ingrowth into calcified cartilage. The connection
emains in late adulthood, when bone tissue forms within
therosclerotic arteries. Epidemiologically, atherosclerosis
nd osteoporosis are closely correlated, even when adjusted
or age and gender (1). Loss of bone in the skeleton occurs
imultaneously with formation of bone in the arterial wall,
aising important questions about mechanisms and current
reatments. For example, do calcium supplements promote
ascular mineralization as much or even more than bone
ineralization? One possible explanation for these concom-
tant but opposite processes is that bone and vascular tissues
See page 1970
ave opposite responses to the same stimulus. In fact, there
s evidence that both disorders are associated with hyper-
ipidemia (2), hypovitaminosis K, and hypervitaminosis D
3–5). More recent investigation of the relationship between
steoporosis and vascular calcification has focused on the
ole of bone proteins in vascular calcification and osteopo-
osis. Proteins initially characterized in bone, including
steopontin (6,7), osteocalcin, bone morphogenetic
rotein-2 (8), matrix gamma-carboxyglutamic acid protein
9), receptor activator of nuclear factor-kappa B ligand
RANK-L) (10), and osteoprotegerin (10,11), are also
resent in atherosclerotic plaques, and they are expressed by
ascular cells in situ and in vitro. Much has been learned
bout the function of some, but the roles of others remain
nigmatic. The overall picture remains incomplete.
In this issue of the Journal, Ueland et al. (12) present data
orrelating the baseline plasma level of the bone protein
steoprotegerin (OPG) with survival and cardiovascular
vents in 234 patients surviving an acute myocardial infarc-
ion (MI). The patients were selected for this substudy from
trial comparing losartan versus captopril after MI. The
PG levels in these patients were significantly higher than
hose in a cohort of healthy, age-matched control subjects.
fter a mean follow-up of about three years, 32 of the
atients died. These patients had a significantly higher
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From the Departments of Medicine, Physiology, and Biomedical Engineering,
niversity of California, Los Angeles, California.aseline OPG level than survivors. After adjustment for
onfounding variables, patients in the highest quartile of
PG levels had an increased risk for mortality, as well as for
composite end point of mortality, nonfatal MI, and stroke.
hese results suggest that elevated OPG may be a useful
arker for a poor prognosis in patients with acute coronary
yndromes complicated by heart failure.
By what mechanism could this bone-regulatory factor
nfluence cardiovascular disease? Bone protein OPG is one
f a trio of powerful interacting molecules now known to
egulate bone turnover. For decades, bone biologists knew
hat differentiation of bone-resorbing osteoclasts from
onocytes required the presence of bone-forming osteo-
lasts, and that osteoclastic activity was carefully balanced
nd coupled with osteoblastic activity. The essential factor
rovided by the osteoblasts was ultimately identified as
ANK-L (Table 1). RANK-L on osteoblasts binds its
eceptor (RANK), (13) a member of the tumor necrosis
actor (TNF) receptor superfamily, on the surface of osteo-
last precursors, including monocytes and macrophages.
he RANK-L binding to RANK activates nuclear factor-
appa B, which, in turn, translocates to the nucleus and
ctivates the Akt/protein kinase B cell survival pathway.
one protein OPG is the third member of this trio, a
ecreted glycoprotein, which was found to act as a soluble
ecoy receptor for the RANK ligand, competing and
reventing activation of RANK on osteoclasts (Fig. 1).
hus, OPG inhibits osteoclast differentiation, and, as ex-
ected, can inhibit forms of osteoporosis.
Also as expected, elimination of OPG gene expression, as
n OPG-deficient mice, results in osteoporosis with in-
reased osteoclast activity. However, these mice also have
he unexpected phenotype of vascular calcification (14). The
oexistence of osteoporosis and vascular calcification in
PG knockout mice has raised interest in the possibility
hat OPG underlies the clinical link between these two
ntities. Based on the vascular phenotype, it is natural to
xpect that OPG should protect the vasculature.
The situation is not simple, however, as indicated by the
ata from Ueland et al. (12), showing a positive association
etween elevated OPG levels and poor cardiovascular prog-
osis. In addition, others have shown that OPG levels are
levated in patients with angiographic coronary artery dis-
ase (15,16), and they correspond to progression of carotid
therosclerosis and development of clinically significant
oronary artery disease (17).
One possible explanation for this apparent paradox lies in
he effects of OPG on inflammation. First, by interfering
ith RANK-L and possibly other members of the TNF
amily signaling pathway, it blocks some aspects of inflam-
ation. In addition, OPG may block another role of
ANK-L—activation of lymphocyte differentiation and
unction. Under normal conditions, RANK-L is most
ighly expressed in lymph node tissue (18), and it enhances
ctivated T-cell survival (19). Mice deficient in RANK-L
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Editorial Comment November 16, 2004:1977–9ave no lymph nodes and abnormal B- and T-cell differ-
ntiation (20). In peripheral blood monocytes, RANK-L
nduces expression of a myriad of inflammatory cytokines,
ncluding TNF-alpha, interleukin (IL)-6, IL-12, IL-1-beta,
nd macrophage inflammatory protein-1-alpha (21). T-cell
xpression of RANK-L is believed to result in the clinically
ignificant bone loss seen in association with rheumatoid
rthritis.
Several lines of evidence suggest a function of OPG in
ascular disease (22). Osteoprotegerin is produced in the
ormal artery wall (23) and in cultured arterial cells such as
oronary smooth muscle cells (24) and endothelial cells (25).
ANK-L and RANK are not expressed in the normal artery
all (23), but they are expressed in calcified arteries of OPG
eficient mice, and they co-localize with osteoclast-like cells
23).
Interestingly, elevated serum OPG may be due to high
ANK-L levels. Mice treated with RANK-L have elevated
erum OPG levels, suggesting a compensatory response to
he effect of RANK-L as part of a negative feedback loop.
or example, IL-2–deficient mice develop profound os-
eopenia and inflammatory colitis associated with hyperac-
ivated T lymphocytes. At four weeks, serum RANK-L
evels are elevated but fall to normal by nine weeks, whereas
erum OPG is normal at four weeks but rises precipitously
y nine weeks. These effects are eliminated by administra-
ion of recombinant OPG at four weeks (26). This example
llustrates the concept that the OPG level alone is not
ufficient to understand its role in pathophysiology; the
elative amount of RANK-L is just as or possibly more
mportant.
Table 1. Nomenclature for the OPG/RANK/R
Factor
Osteoprotegerin (OPG)
Receptor activator of nuclear factor-kappa B
ligand (RANK-L)
RANK
igure 1. Schematic illustrating the interaction of osteoprotegerin (OPG)
ith RANK and the receptor activator of nuclear factor-kappa B ligand
RANK-L). Osteoprotegerin acts as a soluble decoy receptor, blocking
nteraction of RANK-L with its receptor, RANK.Osteoprotegerin may produce even more complex phe-
omena through its effects on other members of the TNF
amily. Soluble CD40 ligand, which is closely related to the
ANK-L (18), is also an independent marker for adverse
utcomes in patients with acute coronary syndromes (27).
ctivation of CD40 increases expression of OPG (28). In
ddition, OPG confers protection from endothelial apopto-
is (6). These multiple effects support the concept advanced
y Ueland et al. (12) that OPG is not merely a biomarker of
nflammation.
Finally, it would not be surprising to find a marker of
eart failure that is also an effective therapy. An example of
his is brain natriuretic peptide. It is difficult to assign a
white hat” or “black hat” categorization to OPG. A more
omplete picture is needed, and rational therapy will need to
ake into consideration, at the least, both vascular and
keletal pathophysiology.
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